针对子宫内膜异位症炎症:新兴的治疗选择
Umberto Perrone1,2, Fabio Barra2,3, Marco Anatrà4,5
1Unit of Obstetrics and Gynecology Viareggio, P.O. Versilia - AUSL Toscana Nord Ovest, Camaiore, Lucca, Italy.
Expert opinion on investigational drugs
|December 24, 2025
概括
新兴的子宫内膜异位症治疗向炎症,而不仅仅是荷尔蒙. 生物剂和抗氧化剂等疗法在减少病变大小和改善疼痛和生育能力方面表现有前途,为那些对传统方法没有反应的女性提供了新的希望.
科学领域:
- 生殖医学是一种生殖医学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 子宫内膜异位症是一种慢性炎症性疾病,影响到10%的生育年龄女性.
- 目前的基于激素的疗法可以缓解症状,但不能解决潜在的免疫失调或炎症.
- 在子宫内膜异位症中,炎症驱动病变的持续性,疼痛和不孕.
研究的目的:
- 审查针对子宫内膜异位症炎症途径的新兴治疗策略.
- 总结涉及子宫内膜异位症进展的关键炎症机制.
- 讨论新型抗炎药物及其潜在的临床应用.
主要方法:
- 关于子宫内膜异位症病理生理学和治疗的当前文献的综述.
- 总结了细胞因子信号传递 (TNF-α,IL-1,IL-6),氧化应激,免疫检查点失调以及JAK/STAT通路的参与.
- 讨论治疗剂,包括生物药物,JAK抑制剂和抗氧化剂.
主要成果:
- 临床前研究表明,通过针对炎症的治疗,减少了病变大小,炎症性细胞因子和氧化应激.
- 早期的临床数据表明,TNF-α,IL-1阻断和N-乙半氨酸可以改善疼痛和生殖结果.
- 生物药物,JAK抑制剂和抗氧化剂代表了有前途的新疗法.
结论:
- 向炎症为子宫内膜异位症管理提供了一个有希望的替代方案,特别是对于荷尔蒙疗法耐药性或生育问题女性.
- 初步证据支持针对炎症的疗法在减少子宫内膜异位症症状和改善治疗结果方面的有效性.
- 未来的研究需要随机试验,长期安全性评估和以生物标志物为导向的分层来进行个性化治疗.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
439
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
439
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
437
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
437
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
454
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
454
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
405
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
405
01:21Inflammatory Bowel Disease V: Surgical Management
423
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
423
01:29Drugs for Treatment of Ulcerative Colitis in IBD
416
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
416